Editas Medicine Depreciation & Amortization Growth & History (EDIT)
Editas Medicine's depreciation and amortization was $5.3M for fiscal 2025.
View full Editas Medicine company overviewEditas Medicine annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.3M | −$532,000 | −9.16% |
| 2024 | 2024-12-31 | $5.8M | −$255,000 | −4.21% |
| 2023 | 2023-12-31 | $6.1M | −$273,000 | −4.31% |
| 2022 | 2022-12-31 | $6.3M | $1.3M | +25.41% |
| 2021 | 2021-12-31 | $5.1M | $1.1M | +27.63% |
| 2020 | 2020-12-31 | $4.0M | $1.1M | +39.89% |
| 2019 | 2019-12-31 | $2.8M | −$424,000 | −13.03% |
| 2018 | 2018-12-31 | $3.3M | $571,000 | +21.28% |
| 2017 | 2017-12-31 | $2.7M | $1.5M | +123.21% |
| 2016 | 2016-12-31 | $1.2M | $731,000 | +155.20% |
| 2015 | 2015-12-31 | $471,000 | $314,000 | +200.00% |
| 2014 | 2014-12-31 | $157,000 | — | — |
Editas Medicine quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $416,000 | −$1.4M | −77.32% |
| Q1 2026 | 2026-03-31 | $483,000 | −$1.4M | −74.80% |
| Q4 2025 | 2025-12-31 | $805,000 | — | — |
| Q3 2025 | 2025-09-30 | $721,000 | −$878,000 | −54.91% |
| Q2 2025 | 2025-06-30 | $1.8M | $414,000 | +29.15% |
| Q1 2025 | 2025-03-31 | $1.9M | $508,000 | +36.05% |
| Q3 2024 | 2024-09-30 | $1.6M | $85,000 | +5.61% |
| Q2 2024 | 2024-06-30 | $1.4M | −$120,000 | −7.79% |
| Q1 2024 | 2024-03-31 | $1.4M | −$135,000 | −8.74% |
| Q3 2023 | 2023-09-30 | $1.5M | −$90,000 | −5.61% |
| Q2 2023 | 2023-06-30 | $1.5M | −$58,000 | −3.63% |
| Q1 2023 | 2023-03-31 | $1.5M | −$14,000 | −0.90% |
| Q3 2022 | 2022-09-30 | $1.6M | $414,000 | +34.79% |
| Q2 2022 | 2022-06-30 | $1.6M | $409,000 | +34.40% |
| Q1 2022 | 2022-03-31 | $1.6M | $395,000 | +33.96% |
| Q3 2021 | 2021-09-30 | $1.2M | $83,000 | +7.50% |
| Q2 2021 | 2021-06-30 | $1.2M | $318,000 | +36.51% |
| Q1 2021 | 2021-03-31 | $1.2M | $365,000 | +45.74% |
| Q3 2020 | 2020-09-30 | $1.1M | $380,000 | +52.27% |
| Q2 2020 | 2020-06-30 | $871,000 | $178,000 | +25.69% |
| Q1 2020 | 2020-03-31 | $798,000 | $170,000 | +27.07% |
| Q3 2019 | 2019-09-30 | $727,000 | −$112,000 | −13.35% |
| Q2 2019 | 2019-06-30 | $693,000 | −$91,000 | −11.61% |
| Q1 2019 | 2019-03-31 | $628,000 | −$123,000 | −16.38% |
| Q3 2018 | 2018-09-30 | $839,000 | $155,000 | +22.66% |
| Q2 2018 | 2018-06-30 | $784,000 | $133,000 | +20.43% |
| Q1 2018 | 2018-03-31 | $751,000 | $120,000 | +19.02% |
| Q3 2017 | 2017-09-30 | $684,000 | $403,000 | +143.42% |
| Q2 2017 | 2017-06-30 | $651,000 | $405,000 | +164.63% |
| Q1 2017 | 2017-03-31 | $631,000 | $444,000 | +237.43% |
| Q3 2016 | 2016-09-30 | $281,000 | $149,000 | +112.88% |
| Q2 2016 | 2016-06-30 | $246,000 | $138,000 | +127.78% |
| Q1 2016 | 2016-03-31 | $187,000 | $104,000 | +125.30% |
| Q3 2015 | 2015-09-30 | $132,000 | — | — |
| Q2 2015 | 2015-06-30 | $108,000 | — | — |
| Q1 2015 | 2015-03-31 | $83,000 | — | — |
Editas Medicine depreciation and amortization trends
Over the last five fiscal years, Editas Medicine's depreciation and amortization increased from $4.0M to $5.3M, a change of $1.3M. The latest reported quarter, Q2 2026, shows $416,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Editas Medicine source filings ↗